Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (Placebo-Controlled, Double-Blind and Randomized Phase III Study of Intravaginal Prasterone)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Prasterone (Primary)
- Indications Decreased libido
- Focus Therapeutic Use
- Acronyms Second Study
- Sponsors Endoceutics
- 01 Feb 2019 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.
- 01 Feb 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 01 Feb 2019 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2019.